Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v3-EN
Language French English
Date Updated 2022-01-05 2022-01-05
Drug Identification Number 02444186 02444186
Brand name BREO ELLIPTA BREO ELLIPTA
Common or Proper name fluticasone furoate/vilanterol (as trifenatate) dry powder for oral inhalation fluticasone furoate/vilanterol (as trifenatate) dry powder for oral inhalation
Company Name GLAXOSMITHKLINE INC GLAXOSMITHKLINE INC
Ingredients VILANTEROL FLUTICASONE FUROATE VILANTEROL FLUTICASONE FUROATE
Strength(s) 25MCG 200MCG 25MCG 200MCG
Dosage form(s) POWDER POWDER
Route of administration INHALATION INHALATION INHALATION INHALATION
Packaging size 1x30 1x30
ATC code R03AK R03AK
ATC description ADRENERGICS, INHALANTS ADRENERGICS, INHALANTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2021-12-15 2021-12-15
Estimated end date 2022-01-04 2022-01-04
Actual end date 2022-01-04 2022-01-04
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments Managing supply due to high demand. Managing supply due to high demand.
Health Canada comments